已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 内科学 卵巢癌 安慰剂 肿瘤科 卵巢癌 双盲 外科 癌症 病理 替代医学
作者
Robert L. Coleman,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I. Weberpals,Andrew R. Clamp,Giovanni Scambia,Alexandra Léary,Robert W. Holloway,Margarita Amenedo,Peter C.C. Fong,Jeffrey C. Goh,David M. O’Malley,Deborah K. Armstrong,Jesús García-Donás,Elizabeth M. Swisher,Anne Floquet
出处
期刊:The Lancet [Elsevier BV]
卷期号:390 (10106): 1949-1961 被引量:1533
标识
DOI:10.1016/s0140-6736(17)32440-6
摘要

Background Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. Methods In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a platinum-sensitive, high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved complete or partial response to their last platinum-based regimen, had a cancer antigen 125 concentration of less than the upper limit of normal, had a performance status of 0–1, and had adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous system metastases, had received anticancer therapy 14 days or fewer before starting the study, or had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-generated sequence (block size of six, stratified by homologous recombination repair gene mutation status, progression-free interval after the penultimate platinum-based regimen, and best response to the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder were masked to assignments. The primary outcome was investigator-assessed progression-free survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is complete. Findings Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant carcinoma was 16·6 months (95% CI 13·4–22·9; 130 [35%] patients) in the rucaparib group versus 5·4 months (3·4–6·7; 66 [35%] patients) in the placebo group (hazard ratio 0·23 [95% CI 0·16–0·34]; p<0·0001). In patients with a homologous recombination deficient carcinoma (236 [63%] vs 118 [62%]), it was 13·6 months (10·9–16·2) versus 5·4 months (5·1–5·6; 0·32 [0·24–0·42]; p<0·0001). In the intention-to-treat population, it was 10·8 months (8·3–11·4) versus 5·4 months (5·3–5·5; 0·36 [0·30–0·45]; p<0·0001). Treatment-emergent adverse events of grade 3 or higher in the safety population (372 [99%] patients in the rucaparib group vs 189 [100%] in the placebo group) were reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most common of which were anaemia or decreased haemoglobin concentration (70 [19%] vs one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none). Interpretation Across all primary analysis groups, rucaparib significantly improved progression-free survival in patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor in the maintenance treatment setting versus placebo could be considered a new standard of care for women with platinum-sensitive ovarian cancer following a complete or partial response to second-line or later platinum-based chemotherapy. Funding Clovis Oncology.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
慕青的应助被科研通管家采纳,获得10
刚刚
核桃的应助被科研通管家采纳,获得30
刚刚
思源的应助被科研通管家采纳,获得10
1秒前
一兜兜糖完成签到,获得积分10
1秒前
1秒前
1秒前
裴之洽闻发布了新的文献求助10
1秒前
啊啊啊啊完成签到,获得积分10
2秒前
假相我哥完成签到 ,获得积分10
2秒前
绿荫完成签到,获得积分20
2秒前
科研通AI6.3的应助被guagua采纳,获得10
3秒前
开心灰狼完成签到 ,获得积分10
3秒前
荔枝完成签到 ,获得积分10
3秒前
朦雨发布了新的文献求助10
4秒前
newbiology完成签到 ,获得积分10
4秒前
会撒娇的糜完成签到 ,获得积分10
4秒前
不万能青年完成签到 ,获得积分10
5秒前
ZZZ完成签到,获得积分10
5秒前
5秒前
5秒前
火星上孤云完成签到 ,获得积分10
5秒前
无语的幻露完成签到,获得积分10
6秒前
CodeCraft的应助被橘子橙子桔子采纳,获得10
6秒前
6秒前
6秒前
爱笑凡旋完成签到,获得积分10
7秒前
zhou完成签到,获得积分10
7秒前
勤奋成威完成签到,获得积分10
8秒前
Owen的应助被绿荫采纳,获得10
8秒前
9秒前
freedom发布了新的文献求助10
9秒前
合适怜南完成签到,获得积分10
9秒前
10秒前
10秒前
Essie完成签到,获得积分20
10秒前
小贾完成签到,获得积分10
12秒前
12秒前
12秒前
萝卜发布了新的文献求助10
13秒前
星辰大海的应助被ZY采纳,获得30
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8172640
求助须知:如何正确求助?哪些是违规求助? 9565334
关于积分的说明 21779243
捐赠科研通 7764434
什么是DOI,文献DOI怎么找? 3431412
关于科研通互助平台的介绍 2555339
邀请新用户注册赠送积分活动 2476401

今日热心研友

tx
11 50
学霸业
7 20
嘻嘻哈哈
60
null
5
注:热心度 = 本日应助数 + 本日被采纳获取积分÷10